Generic competition · all medicines · read 12 November 2026
Is there a generic of Clonidine Hydrochloride, and who makes it?
Clonidine Hydrochloride appears in 5 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 20 generic makers listed as marketed across them. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 4 and 13 years after the first brand approval. This is the Orange Book's listing, not a forecast.
Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.
- Clonidine Hydrochloride appears in 5 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 20 generic makers listed as marketed across them.
- 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
- Where both are dated, the first generic approval came between 4 and 13 years after the first brand approval.
- Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.
Tablet, Oral
Four or more generic makers listed
Every brand product here is listed as discontinued. 9 generic makers with 29 generic products listed as marketed; the first generic approval is dated 8 July 1986.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Actavis Elizabeth Llc | 16 December 1986 | 3 |
| Tp Anda Holdings Llc | 4 September 1987 | 4 |
| Chartwell Molecules Llc | 5 April 1988 | 3 |
| Aurobindo Pharma Ltd | 31 August 1988 | 3 |
| Prinston Pharmaceutical Inc | 9 March 2007 | 3 |
| Unichem Laboratories Ltd | 26 August 2009 | 3 |
| Impax Laboratories Inc | 27 August 2009 | 3 |
| Alembic Pharmaceuticals Ltd | 6 December 2011 | 4 |
| Yung Shin Pharmaceutical Industrial Co Ltd | 13 June 2013 | 3 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Tablet, Extended Release, Oral
Four or more generic makers listed
Every brand product here is listed as discontinued. 7 generic makers with 7 generic products listed as marketed; the first generic approval is dated 30 September 2013.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Actavis Elizabeth Llc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc | 15 May 2015 | 1 |
| Chartwell Rx Sciences Llc | 23 October 2017 | 1 |
| Ajanta Pharma Ltd | 20 November 2017 | 1 |
| Xiamen Lp Pharmacuetical Co Ltd | 20 November 2017 | 1 |
| Jubilant Generics Ltd | 29 January 2018 | 1 |
| Somerset Therapeutics Llc | 12 October 2018 | 1 |
| Novast Laboratories Ltd | 5 March 2019 | 1 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Injectable, Injection
Four or more generic makers listed
Brand listed as marketed: Duraclon. 4 generic makers with 8 generic products listed as marketed; the first generic approval is dated 8 October 2009.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Hikma Farmaceutica (Portugal) Sa | 26 January 2011 | 2 |
| Fresenius Kabi Usa Llc | 8 July 2011 | 2 |
| Xgen Pharmaceuticals Djb Inc | 29 October 2013 | 2 |
| Zydus Pharmaceuticals Usa Inc | 20 February 2014 | 2 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Solution, Oral
Brand listed, no generic listed as marketed
Brand listed as marketed: Javadin and Qlonilik. No generic is listed as marketed.
Patents and exclusivities still listed
- 15 July 2042Patent 12233049 drug product
- 15 July 2042Patent 12721837 drug product
- 15 July 2042Patent 12440474 drug product
- 22 August 2045Patent 12551466 drug product
Suspension, Extended Release, Oral
Brand listed, no generic listed as marketed
Brand listed as marketed: Onyda Xr. No generic is listed as marketed.
Patents and exclusivities still listed
- 29 March 2029Patent 8062667 drug product
- 28 July 2041Patent 11918689 drug product
- 28 July 2041Patent 12576032
US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.
Where can you go from this result?
Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.